3.785
Cytek Biosciences Inc stock is traded at $3.785, with a volume of 505.27K.
It is up +2.30% in the last 24 hours and down -9.88% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$3.70
Open:
$3.76
24h Volume:
505.27K
Relative Volume:
0.62
Market Cap:
$476.52M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-42.06
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
+1.75%
1M Performance:
-9.88%
6M Performance:
-25.64%
1Y Performance:
-34.74%
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CTKB
Cytek Biosciences Inc
|
3.785 | 476.52M | 193.01M | -12.15M | 454.00K | -0.09 |
![]()
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-31-25 | Downgrade | Goldman | Buy → Sell |
Dec-14-23 | Initiated | Stephens | Overweight |
Jul-19-23 | Initiated | Raymond James | Mkt Perform |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Geode Capital Management LLC - Defense World
JPMorgan Chase & Co. Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Is Cytek Biosciences (NASDAQ:CTKB) Using Too Much Debt? - simplywall.st
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Sold by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Decreases Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by American Century Companies Inc. - Defense World
KLP Kapitalforvaltning AS Takes $131,000 Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $3.51 amid market challenges - Investing.com
Trading (CTKB) With Integrated Risk Controls - news.stocktradersdaily.com
Prudential Financial Inc. Has $1.13 Million Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Raymond James Financial Inc. Buys New Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Thrivent Financial for Lutherans Sells 3,001 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cell Analyzer | Cytek Biosciences Inc. | Products - Photonics Spectra
106,597 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Purchased by Teacher Retirement System of Texas - Defense World
Proficio Capital Partners LLC Invests $71,000 in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $3.99 amid market shifts - Investing.com India
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Purchased by PNC Financial Services Group Inc. - Defense World
Cytek Biosciences expands cell analysis offerings with the affordable, user-friendly Cytek Muse Micro System - SelectScience
Charles Schwab Investment Management Inc. Increases Stock Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences (NASDAQ:CTKB) Trading Up 2.2% – What’s Next? - Defense World
Stephens Reiterates “Overweight” Rating for Cytek Biosciences (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $4.05 - Investing.com India
Cytek Biosciences stock hits 52-week low at $4.05 By Investing.com - Investing.com UK
Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System - The Manila Times
Cytek Biosciences Launches Next-Generation Muse Micro Cell Analyzer to Transform Flow Cytometry Accessibility - Nasdaq
Revolutionary Budget-Friendly Cell Analyzer Transforms Biotech Research Accessibility - StockTitan
Bank of New York Mellon Corp Grows Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Proficio Capital Partners LLC Takes Position in Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences stock hits 52-week low at $4.19 amid market challenges - Investing.com Australia
Cytek Biosciences stock hits 52-week low at $4.19 amid market challenges By Investing.com - Investing.com South Africa
Cytek Biosciences (CTKB) to Release Earnings on Wednesday - The AM Reporter
Cytek Biosciences, Inc. (CTKB): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Call Transcript - MSN
Cytek Biosciences (CTKB) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by Principal Financial Group Inc. - Defense World
Cytek Biosciences (NASDAQ:CTKB) Price Target Cut to $8.00 by Analysts at Piper Sandler - Defense World
Cytek Biosciences Reports Mixed Earnings Amid Growth and Challenges - TipRanks
Cytek Biosciences (NASDAQ:CTKB) Hits New 1-Year Low – Here’s Why - Defense World
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges - Investing.com Australia
Is There An Opportunity With Cytek Biosciences, Inc.'s (NASDAQ:CTKB) 22% Undervaluation? - Yahoo Finance
Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Cytek Biosciences stock hits 52-week low at $4.6 amid market challenges By Investing.com - Investing.com South Africa
Cytek Biosciences, Inc. SEC 10-K Report - TradingView
Cytek Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):